Ocugen, Inc. (OCGN)
Pre-market:
- Motley Fool
Where Will Ocugen Be in 1 Year?
The past 18 months have been a roller coaster for Ocugen (NASDAQ: OCGN). Shares of the biotech company skyrocketed in early 2021 after it announced an agreement with India-based Bharat Biotech. The deal stipulated that Ocugen would hold the right to commercialize the Covaxin coronavirus vaccine, which was originally developed by Bharat Biotech, in the U.S. and Canada.
- Motley Fool
Ocugen, Inc. (OCGN) Q1 2022 Earnings Call Transcript
With me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide a financial update. Earlier this morning, we issued a press release, including a business update and first-quarter financial results for 2022.
- Zacks
Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates
Ocugen (OCGN) delivered earnings and revenue surprises of -280% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
